03
Dec
New Delhi, December 03, 2024: SOHM, Inc., a globally recognised pharmaceutical company focused on developing, manufacturing and distributing Generic, Branded Generic, Private label, and Sohm-innovated Pharmaceuticals, Cosmeceuticals and Nutraceutical products, announced the approval of a critical patent by the Japan Patent Office (JPO). This patent safeguards SOHM’s pioneering ABBIE (A Base Binding Integrase Enzyme) genome editing technology, a development poised to significantly impact India’s rapidly evolving biotechnology landscape. The ABBIE technology represents a substantial advancement in gene editing, offering unprecedented precision and safety that could transform treatment approaches for a range of genetic disorders. As India grapples with a considerable…
